Narrative review explores HNRNPA2B1 as a possible regulator of RNA fate in cancer

Photo by Testalize.me / Unsplash

Frontiers in Medicine Published May 28, 2026 Medically reviewed May 28, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Interpret HNRNPA2B1 as a possible RNA fate regulator in cancer, not an established cascade.

This is a narrative review that synthesizes current knowledge on the RNA-binding protein HNRNPA2B1 in cancer. The authors discuss its involvement in various RNA fate modules, including splicing, stability, and translation, across different tumor types. However, they emphasize that the evidence is derived from distinct experimental systems and biological contexts, and should not be interpreted as a single universally established regulatory cascade.

Key findings are qualitative, as no pooled effect sizes are reported. The review highlights HNRNPA2B1 as a possible regulator of selected RNA fate modules rather than an established pan-cancer RNA fate hub. The authors note that mechanisms have largely been described in distinct tumor types, experimental systems, and biological contexts, which limits generalizability.

Limitations acknowledged include the fragmented nature of the evidence and the lack of a unified model. The review does not provide specific practice recommendations, and the certainty of the findings is low due to the narrative synthesis and absence of quantitative synthesis.

Clinicians should interpret these findings cautiously, recognizing that HNRNPA2B1's role in cancer biology is still emerging and not yet clinically actionable.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Cancer progression and treatment failure are increasingly recognized as consequences of tumor plasticity rather than static genetic alterations. A key component of this plasticity is the ability of cancer cells to reprogram RNA fate, thereby reshaping gene expression outputs in response to microenvironmental stress, immune surveillance, infection, and therapeutic pressure. Among RNA-binding proteins involved in post-transcriptional regulation, heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) has been increasingly implicated in several cancer-associated RNA regulatory processes that extend beyond its initial characterization as an N6-methyladenosine (m6A) reader. In this review, we synthesize recent studies showing that HNRNPA2B1 participates in multiple aspects of RNA regulation, including m6A-dependent stabilization of oncogenic lncRNAs and mRNAs, ISGylation-associated selective nuclear export of m6A-tagged transcripts, cytoplasmic translation control, and extracellular vesicle–mediated RNA communication. We further discuss studies associating HNRNPA2B1 with immune–metabolic phenotypes and therapy response, including tumor acidosis, ferroptosis-related pathways, immune evasion, and altered sensitivity to chemotherapy, radiotherapy, endocrine therapy, and targeted treatments. Importantly, these mechanisms have largely been described in distinct tumor types, experimental systems, and biological contexts, and therefore should not yet be interpreted as a single universally established regulatory cascade. Instead, we organize current evidence within a context-aware framework in which HNRNPA2B1 is discussed as a possible regulator of selected RNA fate modules rather than as an established pan-cancer RNA fate hub. By distinguishing experimentally supported mechanisms from hypothesis-generating interpretations, this review provides a balanced assessment of the current evidence, limitations, and therapeutic implications of HNRNPA2B1-related RNA regulation in cancer.